Bank of New York Mellon Corp Purchases 68,451 Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC)

Bank of New York Mellon Corp boosted its holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC) by 22.5% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 373,015 shares of the biopharmaceutical company’s stock after buying an additional 68,451 shares during the period. Bank of New York Mellon Corp owned 0.36% of Revance Therapeutics worth $959,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of RVNC. China Universal Asset Management Co. Ltd. increased its holdings in Revance Therapeutics by 67.2% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 16,981 shares of the biopharmaceutical company’s stock valued at $84,000 after acquiring an additional 6,826 shares during the last quarter. California State Teachers Retirement System increased its holdings in shares of Revance Therapeutics by 9.8% in the first quarter. California State Teachers Retirement System now owns 97,493 shares of the biopharmaceutical company’s stock worth $480,000 after purchasing an additional 8,668 shares during the last quarter. Quest Partners LLC bought a new stake in shares of Revance Therapeutics in the fourth quarter worth about $84,000. EntryPoint Capital LLC lifted its position in shares of Revance Therapeutics by 109.4% in the first quarter. EntryPoint Capital LLC now owns 19,906 shares of the biopharmaceutical company’s stock worth $98,000 after buying an additional 10,400 shares in the last quarter. Finally, Victory Capital Management Inc. bought a new position in Revance Therapeutics during the fourth quarter valued at approximately $93,000. 97.70% of the stock is owned by institutional investors.

Revance Therapeutics Trading Down 0.7 %

Shares of RVNC opened at $5.81 on Friday. The company’s fifty day simple moving average is $5.33 and its 200-day simple moving average is $4.28. The company has a market cap of $606.85 million, a P/E ratio of -1.60 and a beta of 1.00. Revance Therapeutics, Inc. has a twelve month low of $2.30 and a twelve month high of $13.12.

Revance Therapeutics (NASDAQ:RVNC) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.12. The firm had revenue of $65.39 million during the quarter, compared to analysts’ expectations of $66.30 million. During the same period last year, the company earned ($0.80) earnings per share. The business’s revenue for the quarter was up 20.2% compared to the same quarter last year.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on RVNC shares. StockNews.com started coverage on Revance Therapeutics in a research note on Sunday, September 15th. They issued a “hold” rating on the stock. HC Wainwright cut shares of Revance Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 13th. Stifel Nicolaus lowered their price objective on shares of Revance Therapeutics from $24.00 to $20.00 and set a “buy” rating for the company in a research report on Friday, August 9th. Guggenheim reissued a “neutral” rating on shares of Revance Therapeutics in a research note on Monday, August 12th. Finally, William Blair restated a “market perform” rating on shares of Revance Therapeutics in a research report on Monday, August 12th. Ten investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $10.50.

Revance Therapeutics Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.